The Federal Trade Commission (FTC) and four Republican-led states sued the World Professional Association for Transgender Health (WPATH) on Wednesday, alleging the organization misled parents and doctors about the safety, effectiveness, and necessity of transgender medical treatments for minors. The lawsuit claims WPATH failed to adequately disclose potential risks and side effects of puberty blockers, cross-sex hormones, and sex change surgeries.
Core Allegations and Response
The FTC alleges WPATH removed age-based recommendations for certain transgender procedures from its Standards of Care and promoted treatments not sufficiently supported by medical evidence. FTC Chairman Andrew Ferguson stated, 'Parents have a right to make informed decisions about their children's health.' WPATH has not yet publicly responded to the lawsuit.
Background and Context
The lawsuit follows criticism from advocacy groups like 'Do No Harm,' which has raised concerns about the American Psychological Association's (APA) messaging on gender-affirming care. The APA has faced scrutiny for contradictory statements in 2024 and 2025 regarding the safety of such treatments. The FTC's action aligns with broader debates over the regulation of medical guidance for transgender youth.
Policy and Legal Implications
The lawsuit could set a precedent for how medical organizations provide guidance on gender-affirming care. It also highlights tensions between state and federal regulations on healthcare for minors. The case is being heard in the U.S. District Court for the Northern District of Texas, where similar legal challenges have been filed.
Diverse Perspectives
Supporters of gender-affirming care argue that WPATH's guidelines are based on established medical consensus, while critics contend that the organization prioritizes ideological goals over patient safety. The lawsuit has drawn attention to the lack of long-term studies on the effects of transgender medical treatments for minors.